Literature DB >> 12634962

Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86.

Stéphan Walrand1, François Jamar, Isabelle Mathieu, Joëlle De Camps, Max Lonneux, Mérence Sibomana, Daniel Labar, Christian Michel, Stanislas Pauwels.   

Abstract

Several yttrium-90 labelled somatostatin analogues are now available for cancer radiotherapy. After injection, a large amount of the compound is excreted via the urinary tract, while a variable part is trapped in the tumour(s), allowing the curative effect. Unfortunately, the compound may also be trapped in critical tissues such as kidney or bone marrow. As a consequence, a method for assessment of individual biodistribution and pharmacokinetics is required to predict the maximum dose that can be safely injected into patients. However, (90)Y, a pure beta(-)particle emitter, cannot be used for quantitative imaging. Yttrium-86 is a positron emitter that allows imaging of tissue uptake using a PET camera. In addition to the positron, (86)Y also emits a multitude of prompt single gamma-rays, leading to significant overestimation of uptake when using classical reconstruction methods. We propose a patient-dependent correction method based on sinogram tail fitting using an (86)Y point spread function library. When applied to abdominal phantom acquisition data, the proposed correction method significantly improved the accuracy of the quantification: the initial overestimation of background activity by 117% was reduced to 9%, while the initial error in respect of kidney uptake by 84% was reduced to 5%. In patient studies, the mean discrepancy between PET total body activity and the activity expected from urinary collections was reduced from 92% to 7%, showing the benefit of the proposed correction method.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12634962     DOI: 10.1007/s00259-002-1068-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  12 in total

1.  Accelerated image reconstruction using ordered subsets of projection data.

Authors:  H M Hudson; R S Larkin
Journal:  IEEE Trans Med Imaging       Date:  1994       Impact factor: 10.048

2.  Quantitative PET with positron emitters that emit prompt gamma rays.

Authors:  C C Martin; B T Christian; M R Satter; L H Nickerson; R J Nickles
Journal:  IEEE Trans Med Imaging       Date:  1995       Impact factor: 10.048

Review 3.  Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications.

Authors:  M Pagani; S Stone-Elander; S A Larsson
Journal:  Eur J Nucl Med       Date:  1997-10

4.  The ECAT EXACT HR: performance of a new high resolution positron scanner.

Authors:  K Wienhard; M Dahlbom; L Eriksson; C Michel; T Bruckbauer; U Pietrzyk; W D Heiss
Journal:  J Comput Assist Tomogr       Date:  1994 Jan-Feb       Impact factor: 1.826

5.  EM reconstruction algorithms for emission and transmission tomography.

Authors:  K Lange; R Carson
Journal:  J Comput Assist Tomogr       Date:  1984-04       Impact factor: 1.826

6.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.

Authors:  G J Förster; M J Engelbach; J J Brockmann; H J Reber; H G Buchholz; H R Mäcke; F R Rösch; H R Herzog; P R Bartenstein
Journal:  Eur J Nucl Med       Date:  2001-10-20

7.  Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.

Authors:  F Rösch; H Herzog; B Stolz; J Brockmann; M Köhle; H Mühlensiepen; P Marbach; H W Müller-Gärtner
Journal:  Eur J Nucl Med       Date:  1999-04

8.  Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.

Authors:  F Rösch; H Herzog; C Plag; B Neumaier; U Braun; H W Müller-Gärtner; G Stöcklin
Journal:  Eur J Nucl Med       Date:  1996-08

Review 9.  Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Authors:  Marion De Jong; Roelf Valkema; Francois Jamar; Larry K Kvols; Dik J Kwekkeboom; Wout A P Breeman; Willem H Bakker; Chuck Smith; Stanislas Pauwels; Eric P Krenning
Journal:  Semin Nucl Med       Date:  2002-04       Impact factor: 4.446

10.  Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.

Authors:  H Herzog; F Rösch; G Stöcklin; C Lueders; S M Qaim; L E Feinendegen
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

View more
  30 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

2.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

3.  Assessment of the short-lived non-pure positron-emitting nuclide (120)I for PET imaging.

Authors:  H Herzog; S M Qaim; L Tellmann; S Spellerberg; D Kruecker; H H Coenen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-15       Impact factor: 9.236

4.  Is PET always an advantage versus planar and SPECT imaging?

Authors:  Giuliano Mariani; Laura Bruselli; Adriano Duatti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

5.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 6.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

7.  Is bone marrow uptake of ⁸⁶Y-DOTATOC routinely observed?

Authors:  Stephan Walrand; Stanislas Pauwels; François Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

8.  86Y-DOTATOC uptake in red marrow is not routinely visible.

Authors:  Holger Hartmann; Liane Oehme; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-13       Impact factor: 9.236

Review 9.  Accuracy and precision of radioactivity quantification in nuclear medicine images.

Authors:  Eric C Frey; John L Humm; Michael Ljungberg
Journal:  Semin Nucl Med       Date:  2012-05       Impact factor: 4.446

Review 10.  Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  David Taïeb; Philippe Garrigue; Manuel Bardiès; Ahmad Esmaeel Abdullah; Karel Pacak
Journal:  PET Clin       Date:  2015-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.